Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia

Pharmacogenetics and Genomics

Volumn 17, Issue 5, 2007, Pages 305-312

  Inglis, Sally C ^a,b   Herbert, Megan K ^a   Davies, Benjamin J L ^a,b   Coller, Janet K ^b   James, Heather M ^c   Horowitz, John D ^a   Morris, Raymond G ^a,b   Milne, Robert W ^c   Somogyi, Andrew A ^b   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

CYP2D6; Genetic polymorphisms; Perhexiline; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; PERHEXILINE; PEXSIG; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFECT; ENANTIOSELECTIVITY; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; LIVER TOXICITY; NEUROTOXICITY; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE;

BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; MYOCARDIAL ISCHEMIA; PERHEXILINE; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM;

EID: 34247252895     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32800ffba0     Document Type: Article

References (37)

1. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation of ischaemic heart disease. Eur Heart J 2004; 25:634-641.
2. Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36:794-801.
3. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52:273-280.
4. Jeffrey FMH, Alvarez L, Dickzu V, Sherry AD, Malloy CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25:469-472.
5. Seth SD, Choudhury S, Manchanda SC, Gupta MP, Gupta JB. Alterations in isoproterenol-induced cardiac metabolic changes by perhexiline. Indian J Med Res 1985; 81:224-229.
6. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1:193-204.
7. White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3:145-155.
8. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81:1260-1270.
9. Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation 1974; 49:887-893.
10. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112:3280-3288.
11. Stewart S, Voss DW, Northey DL, Horowitz JD. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit 1996; 18:635-639.
12. Willoughby SR, Stewart S, Chirkov YY, Kennedy JA, Holmes AS, Horowitz JD. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 2002; 23:1946-1954.
13. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. BMJ 1982; 284:295-299.
14. Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978; 14:195-201.
15. Horowitz JD, Sia STB, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986; 13:219-229.
16. Amoah AGB, Gould BJ, Parke DV, Lockhart JDF. Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 1986; 16:63-68.
17. Amoah AGB, Gould BJ, Parke DV. Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr 1984; 305:401-409.
18. Cooper RG, Evans DAP, Whibley EJ. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 1984; 21:27-33.
19. Sørensen LB, Sørensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ. Polymorphic hydroxylation of perhexiline in vitro. Br J Clin Pharmacol 2003; 55:635-638.
20. Cooper JDH, Turnell DC, Pilcher J, Lockhart D. Therapeutic monitoring of the anti-anginal drug perhexiline maleate. Ann Clin Biochem 1985; 22:614-617.
21. Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ. Highperformance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 1981; 70:320-322.
22. Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003; 13:627-632.
23. Sallustio BC, Westley IS, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 2002; 54:107-114.
24. Gould BJ, Amoah AGB, Parke DV. Stereoselective pharmacokinetics of perhexiline. Xenobiotica 1986; 16:491-502.
25. Jones TE, Morris RG, Horowitz JD. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state. Br J Clin Pharmacol 2004; 57:263-269.
26. Wright JD, Boudimot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996; 30:445-462.
27. Davies BJ, Herbert MK, Culbert JA, Pyke SM, Coller JK, Somogyi AA, et al. Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B 2006; 832:114-120.
28. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 2004; 42:719-723.
29. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
30. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999; 226:327-338.
31. Morris RG, Sallustio BC, Saccoia NC, Mangas S, Fergusson LK, Kassapidis C. Application of an improved HPLC perhexiline assay to human plasma specimens. J Liq Chromatogr 1992; 15:3219-3232.
32. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11:573-585.
33. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
34. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 2006; 61:321-325.
35. Davies BJL, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, et al. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. Br J Clin Pharmacol 2004; 57:456-463.
36. Cooper RG, Evans DAP, Price AH. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 1987; 32:569-576.
37. Wright GJ, Leeson GA, Zeiger AV, Lang JF. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 1973; 49 (Suppl 3):8-15.